Drug Profile
Hafnium oxide - Nanobiotix
Alternative Names: Hafnium Oxide nanoparticles; Hensify; NBTX 3; NBTXR-3; PEP-503Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Nanobiotix
- Developer LianBio; M. D. Anderson Cancer Center; Nanobiotix; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Radiosensitisers; Small molecules
- Mechanism of Action Free radical stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Squamous cell cancer
- Phase II/III Soft tissue sarcoma
- Phase I/II Rectal cancer; Solid tumours
- Suspended Prostate cancer
- No development reported Breast cancer; Cancer; Colorectal cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Inoperable/Unresectable, Second-line therapy or greater) in USA (Intratumoural, Injection)
- 28 Dec 2023 No recent reports of development identified for phase-I development in Oesophageal-cancer(Combination therapy) in USA (Intratumoural, Injection)
- 26 Dec 2023 LianBio and Janssen Pharmaceutica enters into a development and marketing agreement to develop and commercialize hafnium oxide in China, South Korea, Singapore and Thailand